Prevalence of Deleterious Variants in MC3R in Patients With Constitutional Delay of Growth and Puberty.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
17 Nov 2023
Historique:
received: 14 02 2023
medline: 20 11 2023
pubmed: 20 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

The melanocortin 3 receptor (MC3R) has recently emerged as a critical regulator of pubertal timing, linear growth, and the acquisition of lean mass in humans and mice. In population-based studies, heterozygous carriers of deleterious variants in MC3R report a later onset of puberty than noncarriers. However, the frequency of such variants in patients who present with clinical disorders of pubertal development is currently unknown. This work aimed to determine whether deleterious MC3R variants are more frequently found in patients clinically presenting with constitutional delay of growth and puberty (CDGP) or normosmic idiopathic hypogonadotropic hypogonadism (nIHH). We examined the sequence of MC3R in 362 adolescents with a clinical diagnosis of CDGP and 657 patients with nIHH, experimentally characterized the signaling properties of all nonsynonymous variants found and compared their frequency to that in 5774 controls from a population-based cohort. Additionally, we established the relative frequency of predicted deleterious variants in individuals with self-reported delayed vs normally timed menarche/voice-breaking in the UK Biobank cohort. MC3R loss-of-function variants were infrequent but overrepresented in patients with CDGP (8/362 [2.2%]; OR = 4.17; P = .001). There was no strong evidence of overrepresentation in patients with nIHH (4/657 [0.6%]; OR = 1.15; P = .779). In 246 328 women from the UK Biobank, predicted deleterious variants were more frequently found in those self-reporting delayed (aged ≥16 years) vs normal age at menarche (OR = 1.66; P = 3.90E-07). We have found evidence that functionally damaging variants in MC3R are overrepresented in individuals with CDGP but are not a common cause of this phenotype.

Identifiants

pubmed: 37339320
pii: 7204094
doi: 10.1210/clinem/dgad373
pmc: PMC10655545
doi:

Substances chimiques

Receptor, Melanocortin, Type 3 0
MC3R protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1580-e1587

Subventions

Organisme : NICHD NIH HHS
ID : P50 HD104224
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD090071
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_19009
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R37 HD043341
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_15018
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9815508
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.

Références

J Clin Endocrinol Metab. 2002 Dec;87(12):5581-6
pubmed: 12466356
Mol Metab. 2017 Mar 01;6(5):383-392
pubmed: 28462073
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3693-e3703
pubmed: 33890108
Mol Endocrinol. 2014 Sep;28(9):1547-57
pubmed: 25051171
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
J Clin Endocrinol Metab. 2002 Apr;87(4):1613-20
pubmed: 11932291
Nature. 2021 Nov;599(7886):628-634
pubmed: 34662886
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Mol Metab. 2021 Jun;48:101206
pubmed: 33684608
Arq Bras Endocrinol Metabol. 2012 Dec;56(9):646-52
pubmed: 23329188
Nat Genet. 2017 Jun;49(6):834-841
pubmed: 28436984
EMBO Mol Med. 2016 Jun 01;8(6):626-42
pubmed: 27137492
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Wellcome Open Res. 2019 Mar 14;4:51
pubmed: 31020050
J Clin Endocrinol Metab. 2015 Apr;100(4):E646-54
pubmed: 25636053
Am J Hum Genet. 2018 Oct 4;103(4):522-534
pubmed: 30269813
Cell Genom. 2022 Dec 14;2(12):None
pubmed: 36530175
J Clin Endocrinol Metab. 2008 Mar;93(3):723-8
pubmed: 18160460
Sci Transl Med. 2021 Apr 21;13(590):
pubmed: 33883274
J Clin Endocrinol Metab. 2021 Nov 19;106(12):e5264-e5266
pubmed: 34223894
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Biochem Biophys Res Commun. 2014 Nov 7;454(1):234-8
pubmed: 25450386
Nature. 2021 Nov;599(7885):436-441
pubmed: 34732894
Sci Rep. 2015 Jun 18;5:11208
pubmed: 26084728
Am J Hum Genet. 2013 May 2;92(5):725-43
pubmed: 23643382
Hum Mol Genet. 2020 Aug 11;29(14):2435-2450
pubmed: 32620954
Eur J Endocrinol. 2018 Apr;178(4):377-388
pubmed: 29419413
J Clin Endocrinol Metab. 2023 Nov 17;108(12):e1580-e1587
pubmed: 37339320
Nat Commun. 2020 Mar 24;11(1):1536
pubmed: 32210231
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
N Engl J Med. 2012 Feb 2;366(5):443-53
pubmed: 22296078
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3420-3429
pubmed: 29931354
Endocr Rev. 2019 Oct 1;40(5):1285-1317
pubmed: 31220230
Nat Neurosci. 2017 Mar;20(3):484-496
pubmed: 28166221
Eur J Endocrinol. 2008 Apr;158(4):473-7
pubmed: 18362293
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827

Auteurs

Katie Duckett (K)

Wellcome-MRC Institute of Metabolic Science, Box 289, Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

Alice Williamson (A)

Wellcome-MRC Institute of Metabolic Science, Box 289, Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

John W R Kincaid (JWR)

Wellcome-MRC Institute of Metabolic Science, Box 289, Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

Kara Rainbow (K)

Wellcome-MRC Institute of Metabolic Science, Box 289, Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

Laura J Corbin (LJ)

MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK.

Hilary C Martin (HC)

Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.

Ruth Y Eberhardt (RY)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.

Qin Qin Huang (QQ)

Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.

Matthew E Hurles (ME)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.

Wen He (W)

Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.

Raja Brauner (R)

Pediatric Endocrinology Unit, Hôpital Fondation Adolphe de Rothschild and Université Paris Cité, 25 rue Manin, 75019 Paris, France.

Angela Delaney (A)

Division of Endocrinology, Department of Pediatric Medicine, St. Jude Children's Research Hospital, 262 Danny Thomas Place MS 737, Memphis, TN 38105, USA.

Leo Dunkel (L)

Centre for Endocrinology, William Harvey Research Institute, Barts & the London Medical School, Charterhouse Square, London EC1M 6BQ, UK.

Romina P Grinspon (RP)

Centro de Investigaciones Endocrinolègicas "Dr. César Bergadá" (CEDIE), CONICET-FEI-Divisièn de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Gallo 1330, C1425EFD Buenos Aires, Argentina.

Janet E Hall (JE)

Clinical Research Branch, Division of Intramural Research, National Institute of Environmental Science, National Institute of Health, 111 TW Alexander Dr, Bldg 101 - A222, Research Triangle Park, NC 27709, USA.

Joel N Hirschhorn (JN)

Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.

Sasha R Howard (SR)

Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.

Ana C Latronico (AC)

Departamento de Clínica Médica, Av. Dr. Arnaldo, 455 - Cerqueira César, 01246903 São Paulo - SP, Brazil.

Alexander A L Jorge (AAL)

Departamento de Clínica Médica, Av. Dr. Arnaldo, 455 - Cerqueira César, 01246903 São Paulo - SP, Brazil.

Ken McElreavey (K)

Institut Pasteur, Université de Paris, CNRS UMR3738, Human Developmental Genetics, F-75015 Paris, France.

Verónica Mericq (V)

Institute of Maternal and Child Research, Faculty of Medicine, University of Chile, Santa Rosa 1234, 2° piso, Santiago 8320000, Chile.

Paulina M Merino (PM)

Institute of Maternal and Child Research, Faculty of Medicine, University of Chile, Santa Rosa 1234, 2° piso, Santiago 8320000, Chile.

Mark R Palmert (MR)

Division of Endocrinology, The Hospital for Sick Children and Departments of Pediatrics and Physiology, University of Toronto, Toronto, ON M5G 1X8, Canada.

Lacey Plummer (L)

Massachusetts General Hospital Harvard Center for Reproductive Medicine and Reproductive Endocrine Unit, Massachusetts General Hospital, Bartlett Hall Extension, 5th Floor, 55 Fruit Street, Boston, MA 02114, USA.

Rodolfo A Rey (RA)

Centro de Investigaciones Endocrinolègicas "Dr. César Bergadá" (CEDIE), CONICET-FEI-Divisièn de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Gallo 1330, C1425EFD Buenos Aires, Argentina.

Raíssa C Rezende (RC)

Departamento de Clínica Médica, Av. Dr. Arnaldo, 455 - Cerqueira César, 01246903 São Paulo - SP, Brazil.

Stephanie B Seminara (SB)

Massachusetts General Hospital Harvard Center for Reproductive Medicine and Reproductive Endocrine Unit, Massachusetts General Hospital, Bartlett Hall Extension, 5th Floor, 55 Fruit Street, Boston, MA 02114, USA.

Kathryn Salnikov (K)

Massachusetts General Hospital Harvard Center for Reproductive Medicine and Reproductive Endocrine Unit, Massachusetts General Hospital, Bartlett Hall Extension, 5th Floor, 55 Fruit Street, Boston, MA 02114, USA.

Indraneel Banerjee (I)

Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester M13 9WL, UK.

Brian Y H Lam (BYH)

Wellcome-MRC Institute of Metabolic Science, Box 289, Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

John R B Perry (JRB)

Wellcome-MRC Institute of Metabolic Science, Box 289, Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

Nicholas J Timpson (NJ)

MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK.

Peter Clayton (P)

Paediatric Endocrinology, Royal Manchester Children's Hospital, Oxford Road, Manchester M13 9WL, UK.

Yee-Ming Chan (YM)

Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA.

Ken K Ong (KK)

MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge Biomedical Campus Box 285, University of Cambridge, Cambridge CB2 0QQ, UK.

Stephen O'Rahilly (S)

Wellcome-MRC Institute of Metabolic Science, Box 289, Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH